Editas Medicine Co-founders Present Novel Methods for Improving Genome Editing Specificity in Two Nature Biotechnology Papers

Editas Medicine Co-founders Present Novel Methods for Improving Genome Editing Specificity in Two Nature Biotechnology Papers

April 25, 2014

Findings Advance Therapeutic Potential for CRISPR/Cas9 Technology

Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis

Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis

April 23, 2014

 CAMBRIDGE, Mass., Apr 23, 2014 (BUSINESS WIRE) -- Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene Corporation, presented interim data demonstrating dose dependent increases in hemoglobin in patients with end stage renal disease (ESRD) on hemodialysis.

Avedro Announces Canadian Approval for its KXL II ™ Advanced Cross-Linking System

Avedro Announces Canadian Approval for its KXL II ™ Advanced Cross-Linking System

April 23, 2014

 Offering the Potential for a Non-Surgical Alternative to LASIK

WALTHAM, Mass., Apr 23, 2014 (BUSINESS WIRE) -- Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today the Canadian approval for the company’s KXL II System. The KXL II System performs a procedure called PiXL™ (Photorefractive Intrastromal Cross-Linking) which has the potential to deliver non-surgical correction of myopia, and improve cataract surgery outcomes.

Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency

Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency

April 17, 2014

- First Agios Clinical Program in Inborn Errors of Metabolism -- Third Agios Program to Enter Clinic in Less than a Year -

Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director

Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director

April 14, 2014

 SAN DIEGO, Apr 14, 2014 (GLOBE NEWSWIRE via COMTEX) --Receptos, Inc., a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the appointment of Mary Lynne Hedley, Ph.D. as a director of Receptos. Dr. Hedley will serve as a Class I director with a term of office expiring and to be renewed at the 2014 annual meeting of stockholders. Dr. Hedley will also serve as a member of the Board's Nominating and Corporate Governance Committee. 

TransMedics® Announced Final Results of The PROCEED II Heart FDA Pivotal Trial at ISHLT

TransMedics® Announced Final Results of The PROCEED II Heart FDA Pivotal Trial at ISHLT

April 14, 2014

ANDOVER, Mass., April 14, 2014 /PRNewswire/ -- The PROCEED II heart transplant Food and Drug Administration (FDA) pivotal trial results using the Organ Care System (OCS™) –Heart platform were announced on Saturday, April 12, 2014 at the International Society for Heart and Lung Transplantation (ISHLT) 34th Annual Meeting and Scientific Sessions in

Oasys Water Honored as One of Bloomberg’s 2014 New Energy Pioneers at BNEF’s Future of Energy Summit

Oasys Water Honored as One of Bloomberg’s 2014 New Energy Pioneers at BNEF’s Future of Energy Summit

April 8, 2014

Recognized for its Ability to Change the Energy Landscape Worldwide 

Oasys Water Named 2014 Water Technology Company of the Year

Oasys Water Named 2014 Water Technology Company of the Year

April 8, 2014

Company’s Innovative Forward Osmosis Technology Recognized for its Significant Contributions to the Field of Water Technology

BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes of Lead Cancer Drug Candidate, BIND-014, at AACR 2014 Annual Meeting

BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes of Lead Cancer Drug Candidate, BIND-014, at AACR 2014 Annual Meeting

April 7, 2014

Results Demonstrated Increased Dose Intensity of Weekly Dosing vs. Every Three Week Dosing Schedule of BIND-014 and Utility of PSMA as a Biomarker for Patient Selection

Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers

Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers

April 6, 2014

- Significant Clinical Responses and Reduction of 2HG Biomarker in Early Cohorts -- Data Presented at AACR Corroborate Company’s Precision Medicine Approach in Targeting Cancer Metabolism; Company to Host Investor Webcast on April 6 -